|
Age
|
50(43–55)
|
|
Current smoking, N (%)
|
1(1)
|
|
Hormone receptor status, N (%)
|
|
ER+
|
89(60)
|
|
ER + PR+
|
83(56)
|
|
ER + PR-
|
5(3)
|
|
ER-PR-
|
35(23)
|
|
HER2+
|
12(8)
|
|
ER-PR-HER2-
|
18(12)
|
|
Family history of breast cancer, N (%)
|
25(17)
|
|
Post-menopausal, N (%)
|
111(76)
|
|
Hormone therapy for breast cancer
|
112(76)
|
|
Stage, N (%)
|
|
Stage I
|
33(22)
|
|
Stage II
|
61(41)
|
|
Stage III
|
35(24)
|
|
Missing
|
18(13)
|
|
Recurrence N (%)
|
|
Yes
|
5(3)
|
|
No
|
77(67)
|
|
Unknown
|
65(30)
|
|
Physical activity levels, N (%)
|
|
Low physical activity
|
80(54)
|
|
Moderate physical activity
|
44(30)
|
|
High physical activity
|
23(16)
|
|
Energy intake, Kcal
|
1901(1832–2046)
|
|
Fat intake, grams
|
84 ± 16
|
|
Protein intake, grams
|
56(49–62)
|
|
Carbohydrate intake, grams
|
243 ± 41
|
|
Pre intervention Vitamin D, nmol/liter
|
38(22–62)
|
|
Post intervention vitamin D, nmol/liter
|
110 ± 46
|
|
ApaI N (%)
|
|
AA
|
68(49)
|
|
Aa
|
52(38)
|
|
aa
|
18(13)
|
|
TaqI N (%)
|
|
TT
|
57(41)
|
|
Tt
|
67(49)
|
|
tt
|
14(10)
|
|
BsmI N (%)
|
|
BB
|
66(45)
|
|
Bb
|
65(44)
|
|
bb
|
16(11)
|
|
FokI N (%)
|
|
FF
|
64(44)
|
|
Ff
|
66(45)
|
|
ff
|
17(12)
|
|
Cdx2 N (%)
|
|
GG
|
81(55)
|
|
AG
|
52(35)
|
|
AA
|
14(10)
|
